Prospectively randomized, placebo-controlled phase 3 study to determine the effect of denosumab on breast cancer prevention in BRCA1 mutation carriers
Ended Project Grant Awarded Last action
- Award ID
- W81XWH1910783
- Recipient
-
Verein ZUR Praevention UND Therapie Boesartiger Erkrankungen, Austrian Breast And Colorectal Cancer Study Group UEI X182EYK34L47
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $5,232,648
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Originally
- Place of performance
- Austria
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$703,904 | |
| Amendment | $0 | |
| Amendment | -$26,282 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $5,962,834 |
Quick answers
Who received award W81XWH1910783?
W81XWH1910783 was awarded to Verein ZUR Praevention UND Therapie Boesartiger Erkrankungen, Austrian Breast And Colorectal Cancer Study Group by Defense Health Agency (Department of Defense) on September 15, 2019.
How much is award W81XWH1910783 worth?
$5,232,648 has been obligated on W81XWH1910783.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award